We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

RXi Pharmas Gene Therapy Gets Patent Boost

Rectangle Image
News

RXi Pharmas Gene Therapy Gets Patent Boost

Read time:
 

This patent includes the Company's lead clinical candidate, RXI-109, which is currently being evaluated in multiple clinical trials to reduce scar formation in the skin and eye. The patent, once issued, will not expire until 2031.

"We are pleased to have be granted this Notice of Allowance from the USPTO," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "This patent protection for our novel self-delivering RNAi technology further strengthens our position to generate business and commercial development opportunities in the areas of dermal and ocular scarring as well as other fibrotic indications, such as liver fibrosis".

Advertisement